Tofogliflozin
Tofogliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, promoting urinary glucose excretion (glucosuria) and lowering blood glucose in an insulin-independent manner. It is approved in Japan for type 2 diabetes and is under investigation for non-alcoholic fatty liver disease due to its effects on hepatic steatosis through caloric loss and indirect metabolic improvements. Its selectivity for SGLT2 over SGLT1 reduces the risk of GI adverse effects from intestinal glucose malabsorption.
분자량
386.4000 g/mol
LogP
1.50
TPSA
99.40 Ų
리핀스키 5의 법칙
통과
치료 영역
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D 구조
Cite this structure
Embed this structure
SMILES
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O
InChI
InChI=1S/C22H26O6.H2O/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22;/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3;1H2/t18-,19-,20+,21-,22+;/m1./s1
Molecular Formula
C22H26O6
HBD / HBA
4 / 6
회전 가능 결합
4
무거운 원자
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Tofogliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, promoting urinary glucose excretion (glucosuria) and lowering blood glucose in an insulin-independent manner. It is approved in Japan for type 2 diabetes and is under investigation for non-alcoholic fatty liver disease due to its effects on hepatic steatosis through caloric loss and indirect metabolic improvements. Its selectivity for SGLT2 over SGLT1 reduces the risk of GI adverse effects from intestinal glucose …
Yes, Tofogliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105711. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 46908929. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tofogliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tofogliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tofogliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tofogliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tofogliflozin"></drugfyi-drug>